HOTH THERAPEUTICS INC (HOTH) Stock Price, Quote, News and Overview

Company Profile

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The firm also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.

Company Info

HOTH THERAPEUTICS INC

590 Madison Avenue, 21St Floor

New York City NEW YORK 10020 US

CEO: Robb Knie

Employees: 3

Company Website: https://hoththerapeutics.com/

Investor Relations: http://ir.hoththerapeutics.com

Phone: 16467562997